化合物KS370G T24270

Product Introduction
Bioactivity


英文名: KS370G

描述: KS370G (Caffeic Acid Phenethyl Amide) 抑制 UUO 诱导的肾纤维化标志物表达。KS370G 是一种具有口服活性的降糖和心血管保护剂，可减少梗阻肾脏中胶原蛋白的沉积，并显著降低肾脏炎症趋化因子/粘附分子和单核细胞标志物的表达，改善压力过载小鼠心脏左室肥厚和功能。KS370G 可用于研究肾阻塞性肾病。

体外活性: KS370G (0.35、1.05、1.75、3.5 uM) significantly inhibited the release of nitric oxide (NO) and the expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Treatment with KS370G also induced heme oxygenase (HO)-1 and suppressors of cytokine signaling (SOCS)-3 expression in the microglia. Furthermore, the anti-inflammatory effects of KS370G were found to be regulated by phosphorylated adenosine monophosphate-activated protein kinase-α (AMPK-α) translocated to the nucleus. Moreover, KS370G showed significant anti-neuroinflammatory effects on microglial activation in vivo and on motor behavior as well.[3]

体内活性: KS370G 1mg/kg (1mg/kg; chronic oral gavage; once a day) inhibited cardiac hypertrophy and improved cardiac function induced by pressure overload. KS370G also decreased the plasma levels of atrial natriuretic peptide and lactate dehydrogenase. Besides, pressure overload-induced increases of α-SMA and phosphorylation of ERK, AKT, and GSK3β were significantly reduced by chronic oral treatment with KS370G. We also found that chronic oral treatment with KS370G reduced cardiac collagen accumulation. KS370G improved left ventricular function and inhibited cardiac hypertrophy through the decrease of the phosphorylation of ERK, AKT, and GSK3β in pressure-overload mice hearts.[4]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 45 mg/mL (158.83 mM)


关键字: KS370G

相关库: Bioactive Compounds Library Max | Bioactive Compound Library

化合物KS370G T24270信息由TargetMol中国为您提供，如您想了解更多关于化合物KS370G T24270报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途